AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Wedge, Stephen R.; Kendrew, Jane; Hennequin, Laurent; Valentine, Paula J.; Barry, Simon T.; Brave, Sandra R.; Smith, Neil R.; James, Neil H.; Dukes, Michael; Curwen, Jon; Chester, Rosemary; Jackson, Janet A.; Boffey, Sarah J.; Kilburn, Lyndsey L.; Barnett, Sharon; Richmond, Graham H.P.; Wadsworth, P.F.; Walker, Mike; Bigley, Alison; Taylor, Sian; Cooper, Lee; Beck, Sarah; Jürgensmeier, Juliane M.; Ogilvie, Donald

doi:10.1158/0008-5472.can-04-4409

articleCancer ResearchMay 15, 2005BRONZE OA

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

SRStephen R. Wedge JKJane Kendrew LHLaurent Hennequin PJPaula J. Valentine STSimon T. Barry

Bioscience Research · AstraZeneca (France) · +2 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Inhibition of vascular endothelial growth factor-A (VEGF) signaling is a promising therapeutic approach that aims to stabilize the progression of solid malignancies by abrogating tumor-induced angiogenesis. This may be accomplished by inhibiting the kinase activity of VEGF receptor-2 (KDR), which has a key role in mediating VEGF-induced responses. The novel indole-ether quinazoline AZD2171 is a highly potent (IC50

Citation impact

710

total citations

FWCI: 17.94
Percentile: 100%
References: 68

Citations per year

Authors

24

Topics & keywords

Topics

Keywords

Angiogenesis
Endocrinology
Vascular endothelial growth factor
Internal medicine
Tyrosine-kinase inhibitor
Neovascularization
Biology
Kinase insert domain receptor

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.